Obviously you’ve never had a satsuma. No one would dare to bruise them in a fight. |
DP. There is some evidence HRT may help, to some degree, but not a cure, and in some cases (like muscle pain) the effect is small and possibly outweighed by risks. Not to mention that there are so many different formulations of HRT that the dosages and combinations people are on have not been fully studied. I will consider HRT if my hot flashes start to disrupt sleep badly (but I will also look into the other new meds). I will ask my doctor about whether they recommend a DEXA scan to see if taking HRT to prevent osteoporosis makes sense. Otherwise, all the rest of the benefits are so far from being proven or as significant as those two that there’s no reason to even consider them in the calculus. |
Wow. Umm. |
But no one wrote that. You’ve misinterpreted that post, per your apparent usual. Are you a researcher or a physician? |
I don't know why it's necessary to question this. It's clear that there is a small absolute increase in the risk of breast cancer from taking combined (not estrogen-only, but if you have a uterus, you need combined, i.e. estrogen + progestin) HRT -- an annual increase in risk of about 0.1% per year. Over five years, that means the risk rises from roughly 23 in 1000 women (without HRT) to 28 in 1000 women (with HRT). That's real. The question really isn't whether that risk exists, it's about the risk-benefit ratio for each individual. |
|
For those who want data and official medical positions, here's some research on HRT and type 2 diabetes. Summarizing, it shows that across multiple large randomized trials and meta-analyses, HRT with estrogen (with or without progestin) reduces the risk of developing type 2 diabetes on the order of 20–30% and improves insulin resistance and glucose control:
Margolis KL et al., Diabetologia 2004 — 15,641 postmenopausal women randomized and placebo controlled: https://link.springer.com/article/10.1007/s00125-004-1448-x Mauvais-Jarvis et al. 2017 – Endocrine Reviews https://academic.oup.com/edrv/article/38/3/173/3063786 Note that HRT does not have an FDA-approved prevention indication. The North American Menopause Society in their 2022 position statement said that they do NOT recommend starting HRT primarily to prevent diabetes, but that a diabetes-preventive effect is a real, evidence-based benefit in appropriate women (younger, early postmenopause): https://pubmed.ncbi.nlm.nih.gov/35797481/ |
Many people on this thread have implied or stated that HRT is more beneficial than it is. That particular PP seemed to be implying that HRT is so beneficial that it will meaningfully reduce the number of women who need diabetes meds, SSRIs, and osteoporosis meds. |
Lol, "researcher".
|
Sure. But since we are being so detailed about the absolute of HRT it is also important to be detailed about the absolute benefits: “The cumulative incidence of treated diabetes was 3.5% in the hormone therapy group and 4.2%” So there was 0.7% fewer diabetes cases in the HRT group. Hardly a stunning number on an individual level. These findings are probably most important to conclude that a woman with diabetes or at risk of it can take HRT without a negative impact on diabetes. |
Oh! Oh! Now do breast cancer risk!!!!! Let’s see those research skillz that clearly pay the bills. That is, if you’re not busy getting a lube-free fk from your devoted DH right now as you stalk this thread all day. |
|
Re heart disease, the most important study is proably Hodis & Mack 2022, because it pulls together data from previous randomized trials, meta-analyses, and observational studies. This paper shows that timing is everything. When initiated in women <60 or <10 years since menopause, HRT reduces coronary heart disease events and all-cause mortality by roughly 30–50%, with no increase in stroke in this age/timing group. When started later, though, HRT shows no benefit and may be associated with increased risks. https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928
There are plenty of other papers on the topic, but Hodis & Mack incorporate and synthesize them. As with type 2 diabetes, HRT does not have FDA approval for prevention of heart disease. And, similar to type 2 diabetes, The NAMS 2022 statement does not recommend starting HRT primarily to prevent cardiovascular disease, but they acknowledge that randomized trials, meta-analyses, and observational data suggest fewer cardiovascular events in *appropriately selected* (i.e. younger women who initiate HRT near menopause), and that overall benefits outweigh risks for most healthy symptomatic women <60 or within 10 years of menopause. |
Wow. You truly are not making the case that the HRT discourse is impartial. Take a step back please. |
Thanks. part of my concern with this research is that it uses (I believe) standardized dosages, types and delivery methods of hormones. Whereas there is much more varied in how HRT is actually prescribed in real life. |
I did that above. |
Correct, the absolute difference was 0.7%. That represents a 21% reduction in diabetes risk relative to the placebo -- that's the real effect. Note that the data were from the WHI, which had an average age of 63, and enrolled many women who were more than 10 years post menopause. The effect would likely be larger among women <60 but we don't have that data. |